Niagen Bioscience, Inc. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. The company is headquartered in Los Angeles, California and currently employs 117 full-time employees. The company went IPO on 2007-06-25. Its segments include Consumer Products, Ingredients segment, Analytical Reference Standards and Services and Pharmaceuticals. The Consumer Products segment provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors. The ingredients segment develops and commercializes proprietary-based ingredient technologies, including food-grade Niagen and pharmaceutical-grade Niagen, and supplies these ingredients as raw materials to the manufacturers of consumer products and outsourcing facilities. The Analytical Reference Standards and Services segment offer the supply of phytochemical reference standards and other research and development services. The Pharmaceutical segment focuses on the pharmaceutical development of its nicotinamide adenine dinucleotide (NAD) precursor portfolio for potential therapeutic applications in rare diseases.
Mr. Robert Fried is the Chief Executive Officer of Niagen Bioscience Inc, joining the firm since 2015.
What is the price performance of NAGE stock?
The current price of NAGE is $0, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Niagen Bioscience Inc?
Niagen Bioscience Inc belongs to Consumer products industry and the sector is Consumer Staples
What is Niagen Bioscience Inc market cap?
Niagen Bioscience Inc's current market cap is $NaN
Is Niagen Bioscience Inc a buy, sell, or hold?
According to wall street analysts, 7 analysts have made analyst ratings for Niagen Bioscience Inc, including 4 strong buy, 6 buy, 1 hold, 0 sell, and 4 strong sell